Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

A compound which has the structure

• wherein
• m is 0, 1 or 2;
• n=0, 1 or 2;
• Q is C
• A is (CH2)x where x is 1 to 5;
• or A is (CH2)x1, where x1 is 2 to 5, with an alkenyl bond or an alkynyl bond embedded in the chain;
• or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0,
• X1 is CH
• X2 is O or S;
• X3 is CRc;
• X4 is NRf, wherein Rc selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino, and Rf selected from a single bond, H, alkyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl, provided that at least one of X2, X3 and X4 is
• E is NRg;
• M is Rj;
• G is O or S, wherein Rg is selected from a single bond, H, alkyl, aryl, cycloalkyl, heteroaryl or cycloheteroalkyl;
• and Rj is selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino,
• provided where in each of X1 through X4 as defined above, C may include CH;
• R1 is H or alkyl;
• R2 is H, alkyl, alkoxy, halogen, amino or substituted amino;
• R2a, R2b and R2c are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;
• R3 is selected from aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, arylalkenyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxycarbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl, or polyhaloalkylaryloxycarbonyl;
• Y is CO2R4 (where R4 is H or alkyl, or a prodrug ester) or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR4a)R5 (R5 is alkyl or aryl, or a phosphonic acid of the structure P(O)(OR4a)2 (where R4a is H or a prodrug ester);
• (CH2)x, (CH2)x1, (CH2)x2, (CH2)x3, (CH2)m, and (CH2)n may be optionally substituted with 1, 2 or 3 substituents;
• stereoisomers thereof, a prodrug ester thereof, and a pharmaceutically acceptable salt thereof.